Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Corporate Update (April 2026)
19 slides from Invivyd's corporate update, Apr 9, 2026
Slide 1: REVOLUTION Program & Measles
REVOLUTION Program & Measles April 9, 2026 © 2026 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Agenda
AGENDA 01 02 03 REVOLUTION Measles Q&A Program Updates Program Review
Slide 4: COVID remains pervasive and shortens lifespans; vaccines generated >$6B revenue in 2025
COVID remains pervasive and shortens lifespans; despite controversy, vaccines generated >$6B revenue in 2025 Each (re)infection accumulates risk Spike protein is now a ubiquitous environmental toxin Overt cardiovascular, renal, vascular and neurologic risks manifest either in acute morbidity and mor
Slide 5: Monoclonal antibodies can change the game
Monoclonal antibodies can change the game Inspired by natural maternal-fetal passive antibody transfer Engineered to exceed natural human immune limits Antibody supplementation offers unique merits in infectious disease: Equitable, immediate protection Anticipated high, durable protection No spike p
Slide 6: Invivyd is at a critical point in its evolution
Invivyd is at a critical point in its evolution, as is infectious disease prevention Adintrevimab 1st-generation mAb investigated for pandemic pre-Omicron variants Investigational mAb authorized by U.S. FDA* Pemivibart Maintained neutralization potency against historical and current variants for ~4
Slide 7: VYD2311 study: increased events sample size
VYD2311 STUDY Increased Events Sample Accumulated pooled, blinded PCR-positive COVID events can already provide sufficient Accumulating Size statistical power to support high end of anticipated efficacy On-T Increased ck Event Pre-specified, conservative sample size re-estimation algorithm triggers
Slide 8: VYD2311 mAb & Vaccine Safety & Immunology Study; Pediatric Study
VYD2311 mAb & Vaccine Safety & Immunology Study Pediatric Study Final protocol submitted to FDA Aligned with FDA on Initial Pediatric 3 Arms: Study Plan to support BLA filing (1) VYD2311 (2) mRNA Vax (3) VYD2311+mRNA Vax Plan for single study to assess the immunogenicity Operational start-up activit
Slide 9: Cicada is an interesting virus, even if unable to drive a wave
Cicada is an interesting virus, even if unable to drive a wave Cicada (BA.3.2) Highly divergent lineage from dominant JN.1 — emerged from dormant, ancestral BA.3 Reduced ACE2 binding theoretically may prevent dominance and limit emergence to periods of low competition Meaningfully reduced neutraliza
Slide 10: Measles Program
MEASLES PROGRAM Development Epidemiology & Standard-of-Care Use Cases Next Steps Candidate: VMS063 Burden of Disease
Slide 11: VMS063 novel pan-measles variant antibody candidate
VMS063 a novel, highly potent, half-life extended, pan-measles variant antibody candidate advancing towards IND-enabling studies Targets highly conserved epitope on measles Fusion (F) protein, a trimeric fusion protein responsible for viral membrane fusion Exhibits low single digit nanogram / millil
Slide 12: U.S. facing sustained resurgence of measles outbreaks
The U.S. is facing a sustained resurgence of measles outbreaks, driven by decreasing population immunity US Annual Measles Case measles cases in the U.S. in 2025 As of March 2026 >2,200 —a 30-year high 2,500 2,000 >1,500 measles cases in the U.S. in the first quarter of 2026 alone Case 1,500 current
Slide 13: Measles is one of the most contagious known infections
Measles is one of the most contagious known infections, with potentially life-threatening outcomes and severe long-term complications 1out of 5 1out of 1,000 Unvaccinated cases are hospitalized Unvaccinated cases develop encephalitis 1-3out of 1,000 1out of 10,000 Unvaccinated cases result in death
Slide 14: More tools are urgently needed
More tools are urgently needed VACCINATION TREATMENT & PEP Vaccination is highly effective (~97% VE) and is gold- No FDA-approved treatments; Pooled Plasma Immune standard prophylaxis, though risk remains, with ~8% of Globulin (IG) and vitamin A used off-label with limited 2026 U.S. infections in va
Slide 15: Serum antibody titers are a correlate of protection for measles
Serum antibody titers are a correlate of protection for measles, and useful in post-exposure prophylaxis Measles infection is highly susceptible to antibodies IG reduced clinical infections by >80% in PEP for measles A highly-specific, engineered mAb is well Pre-exposure measles antibody titers are
Slide 16: VMS063 could be leveraged for treatment or prevention
VMS063 could be potentially leveraged for both treatment or prevention Treatment of symptomatic measles, with the aim TREATMENT of shortening duration of symptoms and reducing severe complications POST-EXPOSURE Post-exposure passive prophylaxis to prevent PROPHYLAXIS or respond to outbreaks PRE-EXPO
Slide 17: Measles next steps
MEASLES NEXT STEPS Initiated outreach to Expect initial proof-of-concept Expect IND-readiness FDA to discuss potential data in early treatment setting, by year-end 2026 regulatory pathways subject to regulatory feedback
Slide 18: Pipeline
PIPELINE PROGRAM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL Pemivibart COVID VYD2311 COVID VBY329 RSV VMS063 Measles Mumps Rubella HMPV Borrelia Lyme PIV Pertussis RSV: respiratory syncytial virus; HMPV: Human metapneumovirus; PIV: Human parainfluenza viruses
Slide 19: Invivyd Inc.
INVIVYD INC.